Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Generative biology combines artificial intelligence (AI), advanced life sciences technologies,
and automation to revolutionize the process of designing novel biomolecules with …

Biologic drug discovery pipelines are designed to deliver protein therapeutics that have
exquisite functional potency and selectivity while also manifesting biophysical …

Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are
essential to achieve the desired pharmacological benefits in patients. To accomplish this, we …

Phage therapy has shown great promise for the treatment of multidrug-resistant bacterial
infections. However, the lack of a thorough and organized understanding of phage–body …

ABSTRACT A model-based framework is presented to predict monoclonal antibody (mAb)
pharmacokinetics (PK) in humans based on in vitro measures of antibody physiochemical …

Motivated by a series of work demonstrating the effect of molecular charge on antibody
pharmacokinetics (PK), physiological-based pharmacokinetic (PBPK) models are emerging …

Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the
immunosuppressive tumor microenvironment remains a major barrier to their efficacy …

There has been an increasing trend towards subcutaneous (SC) delivery of fusion proteins
and monoclonal antibodies (mAbs) in recent years versus intravenous (IV) administration …

The main objective of this manuscript was to validate the ability of the monoclonal antibody
physiologically-based pharmacokinetic (PBPK) model to predict tissue concentrations of …